Trial to Investigate the in Silico Optimization of Insulin Treatments

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2018
The hypothesis of the study is that settings for the Glucommander protocol can be optimized in silico to achieve statistically improved low blood glucose index (LBGI) within the subpopulation of CABG and valve replacement patients who both receive Glucommander‐based insulin therapy and meet Manufacturer's guidelines for starting with an initial multiplier value of .052, without risking clinically significant increase in exposure to hyperglycemia.
Epistemonikos ID: 2dc1719233db66bc474a4a8196ec6b8bb8655009
First added on: May 22, 2024